#vtak hashtag - Bluesky

VTAK Announces Definitive Merger Agreement to Acquire 100% of Fly Flyte Inc. VTAK (NYSE American: VTAK) completed acquisition of the remaining 80.02% equity interest in Fly Flyte, making Flyte a wholly owned subsidiary and consolidating a revenue-generating, asset-backed regional aviation platform.Flyte operates under FAA 14 CFR Part 135 using certified Cirrus Vision Jets, providing immediate cash flow, tangible aircraft and infrastructure, and consolidated revenues going forward.

3 weeks ago

#VTAK VTAK Announces Definitive Merger Agreement to Acquire 100% of Fly Flyte Inc.

www.stocktitan.net/news/VTAK/vtak-announces...

0 0 0 0

Catheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at ISLAA 2026 Catheter Precision (NYSE American: VTAK) said its LockeT suture retention device will be featured in live procedural cases at the International Symposium of Left Atrial Appendage (ISLAA) 2026, held March 5–6, 2026, in Los Angeles.Company representatives will provide hands-on demonstrations for electrophysiology fellows and highlight LockeT benefits including potential cost reduction and same-day discharge.

4 weeks ago

#VTAK Catheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at ISLAA 2026

www.stocktitan.net/news/VTAK/catheter-preci...

0 0 0 0

Catheter Precision Receives First Purchase Order for LockeT in Germany Catheter Precision (NYSE/American: VTAK) announced receipt of its first LockeT purchase order in Germany from Universitätsklinikum Frankfurt on January 22, 2026. The order marks LockeT's official entry into the German market and installs the company's suture retention device designed to improve workflow after venous catheter access while remaining cost effective. Catheter Precision cited Germany as the largest healthcare market in Europe and referenced a $900 million German electrophysiology devices market size for 2024. The Frankfurt university hospital will act as a reference site as the company scales operations across Germany and broader Europe.

2 months ago

#VTAK Catheter Precision Receives First Purchase Order for LockeT in Germany

www.stocktitan.net/news/VTAK/catheter-preci...

0 0 0 0

Catheter Precision Received new VIVO Purchase Order from Leading Hospital in Slovenia Catheter Precision (NYSE American: VTAK) received a VIVO purchase order from University Clinical Center Ljubljana, a leading public hospital in Slovenia, expanding the company’s global commercial footprint to 15 countries. The company said the order and recent entries validate VIVO and LockeT adoption by physicians and follow a year of growth driven by distribution partnerships and ongoing navigation of international regulatory processes as it pursues further expansion in 2026.

2 months ago

#VTAK Catheter Precision Received new VIVO Purchase Order from Leading Hospital in Slovenia

www.stocktitan.net/news/VTAK/catheter-preci...

0 0 0 0

Ireland’s largest heart‑rhythm center adopts a new device to boost EP safety Catheter Precision lands a multi-year LockeT commitment from Mater Private Dublin, training 52 staff in 2 days at a center with 1,000+ EP cases a year.

3 months ago

#VTAK Catheter Precision (VTAK) Announces Expansion of LockeT into an Eighth European Country Since Receipt of CE Mark

www.stocktitan.net/news/VTAK/catheter-preci...

0 0 0 0

Catheter Precision (NYSE American: VTAK) secures multi-year VIVO tender in Hungary Catheter Precision’s VIVO system lands a multi-year tender at Szeged University Hospital, marking its first Hungary installation, targeted for Q1 2026.

4 months ago

#VTAK Catheter Precision Secures Tender From Leading Hospital in Hungary

www.stocktitan.net/news/VTAK/catheter-preci...

0 0 0 0

4 months ago

#VTAK Catheter Precision Announces Launch of LockeT in Switzerland

www.stocktitan.net/news/VTAK/catheter-preci...

0 0 0 0

Historic Win for Electrophysiology Reimbursement in Ambulatory Surgery Centers Provides Unique Opportunity for Catheter Precision’s LockeT Device Catheter Precision (NYSE:VTAK) said the Centers for Medicare and Medicaid services will add electrophysiology ablation codes to the ASC-Covered Procedures List effective January 1, 2026, a policy change that expands Medicare beneficiary access to EP services in ambulatory surgery centers. The company framed the change as a new commercialization opportunity for its LockeT suture retention device, saying ASCs seek cost‑effective, workflow‑improving products that enable same‑day discharge and quick hemostasis. The announcement highlights potential for additional patient scheduling and new ASC facilities to adopt LockeT.

4 months ago

#VTAK Historic Win for Electrophysiology Reimbursement in Ambulatory Surgery Centers Provides Unique Opportunity for Catheter Precision’s LockeT Device

www.stocktitan.net/news/VTAK/historic-win-f...

0 0 0 0

Catheter Precision Announces Successful LockeT Launch in South Africa Catheter Precision (NYSE:VTAK) announced rapid commercial uptake of its LockeT closure device in South Africa on Nov 20, 2025. With distributor HLC Medical and Dr. Heather Henry-Lines, LockeT was implemented in five hospitals within two months; three hospitals use LockeT daily and two use it routinely. Two additional hospitals are awaiting internal approvals. All five hospitals have placed reorders through the distributor. Management highlighted LockeT as cost effective, workflow-improving, and supportive of rapid hemostasis enabling same-day discharge.

4 months ago

#VTAK Catheter Precision Announces Successful LockeT Launch in South Africa

www.stocktitan.net/news/VTAK/catheter-preci...

0 0 0 0

4 months ago

#VTAK Catheter Precision Announces Third VIVO Installation in France

www.stocktitan.net/news/VTAK/catheter-preci...

0 0 0 0

Catheter Precision (VTAK) Reports Third Quarter and First Nine Months 2025 Results of Operations Catheter Precision (NYSE American: VTAK) reported Q3 2025 revenue of $226,000, up 135% vs Q3 2024, and nine-month revenue of $581,000, up 114% vs YTD 2024.GAAP net loss for Q3 2025 was $2,251,000, a 45% reduction from Q3 2024; nine-month GAAP net loss was $11,405,000 vs $11,015,000 year‑earlier. Non‑cash charges were $4,232,000 for the nine months.Commercially, the company cited a Q2 CE Mark for LockeT, growing international interest (Germany, France, Italy, Spain, Portugal, UK, South Africa), five South Africa reorders in October, and the first VIVO purchase order from France. Management said two VIVO clinical studies completed in 2025 delivered clinical evidence supporting VIVO's clinical potential.

4 months ago

#VTAK Catheter Precision (VTAK) Reports Third Quarter and First Nine Months 2025 Results of Operations

www.stocktitan.net/news/VTAK/catheter-preci...

0 0 0 0

Catheter Precision Enters Distribution Agreement with FuMedica AG to Bring LockeT to Switzerland Catheter Precision (NYSE/American: VTAK) announced a distribution agreement with FuMedica AG to introduce the LockeT suture retention device to hospitals and clinics across Switzerland, effective October 16, 2025. LockeT is described as a tool to simplify and secure closure of vascular access sites after cardiac procedures, aimed at electrophysiology labs and interventional suites. FuMedica AG will leverage its Swiss clinical relationships and support capabilities to promote LockeT as part of Catheter Precision’s European expansion.

5 months ago

#VTAK Catheter Precision Enters Distribution Agreement with FuMedica AG to Bring LockeT to Switzerland

www.stocktitan.net/news/VTAK/catheter-preci...

0 0 0 0

Breaking: Two Groundbreaking Heart Treatment Patents Awarded to Catheter Precision for Arrhythmia and Heart Failure Medical device company receives patents for ventricular arrhythmia localization and neurostimulation technology. Innovations target cardiac electrophysiology and heart failure treatment markets.

6 months ago

#VTAK Catheter Precision, Inc. Announces Two New Patents to be Issued by USPTO

www.stocktitan.net/news/VTAK/catheter-preci...

0 0 0 0

Leading Croatian Hospital Chooses Catheter Precision's VIVO System After Exceeding Accuracy Expectations Dubrava University Hospital places first Croatian order for Catheter Precision's VIVO cardiac mapping system following successful evaluation. Hospital treats 25,000 inpatients annually.

6 months ago

#VTAK Catheter Precision Announces Tender Win and First Purchase Order in Croatia

www.stocktitan.net/news/VTAK/catheter-preci...

1 0 0 0

Medical Device Maker Catheter Precision Schedules Key Stockholder Vote on Share Authorization Cardiac device company Catheter Precision (VTAK) sets Sept 10 record date for Oct 10 special meeting to vote on increasing authorized shares and appointing WithumSmith+Brown as FY2026 auditor.

6 months ago

#VTAK Catheter Precision Announces September 10th, 2025 Record Date for October 10th, 2025 Special Meeting of Stockholders

www.stocktitan.net/news/VTAK/catheter-preci...

0 0 0 0

Medical Device Breakthrough: Catheter Precision's LockeT Gains Italian Market Entry After France & Germany Success Catheter Precision receives first Italian commercial order for LockeT cardiac closure device following successful procedures at ASST Valle Olona Hospital. Expands European presence to third market.

7 months ago

#VTAK Catheter Precision Announces Introduction of the LockeT Product Line into Italy

www.stocktitan.net/news/VTAK/catheter-preci...

0 0 0 0

First-Ever French LockeT Cardiac Procedures: Catheter Precision Expands Revolutionary Post-Ablation Tech Medical device company Catheter Precision achieves milestone with first LockeT cardiac procedures at CHU Rennes, France. Follows recent CE Mark approval and VIVO partnership.

7 months ago

#VTAK Catheter Precision Announces First Procedures in France as LockeT Expansion Continues

www.stocktitan.net/news/VTAK/catheter-preci...

0 0 0 0

Revolutionary 3D Heart Model Patent: Catheter Precision Expands VIVO Arrhythmia Detection Technology Medical device company Catheter Precision receives USPTO patent for noninvasive ventricular arrhythmia localization using 3D heart modeling, expanding VIVO product line IP portfolio.

7 months ago

#VTAK Catheter Precision Receives Notification of New Patent Issuance for VIVO Product Line

www.stocktitan.net/news/VTAK/catheter-preci...

0 0 0 0

7 months ago

🚨 FeetrAI Alert: #VTAK is in the spotlight! Trading at $3.02, it's below key SMAs with RSI at 44. MACD hints at a bounce, but caution is advised. Consider a SHORT at $3.05, targeting $2.85 & $2.70. Stop loss at $3.20. Stay sharp for news or sector shifts! 📉 #StockMarket #Biotech

0 0 0 0

7 months ago

🚨 FeetrAI Alert: #VTAK is in the spotlight! Trading at $3.02, it's showing mixed signals with a potential bearish trend but a hint of bullish reversal. Volume spikes suggest speculative interest. Consider a short position with targets at $2.90 & $2.80. Stay vigilant! 📉📈

0 0 0 0

7 months ago

🚨 Exciting times for #VTAK! After a 1-for-19 reverse split, volatility is up! 📉 Bearish trend with RSI at 42 hints oversold. MACD suggests a short-term bounce. Consider shorting at $2.90, targeting $2.70 & $2.50. Stop loss: $3.10. Stay alert for news! #FeetrAI #StockWatch

0 0 0 0

7 months ago

🚨 FeetrAI Alert: #VTAK just executed a 1-for-19 reverse split, sparking short-term volatility! 📉 With bearish momentum and RSI at 44, a SHORT position is advised. Entry: $2.95, Targets: $2.80 & $2.60, Stop Loss: $3.10. Watch volume & sentiment closely! 📊 #StockMarket #TradingTips

0 0 0 0

100-Patient Clinical Trial: Catheter Precision's LockeT Takes On Traditional Closure Devices in Safety Study Medical device company initiates single-center study comparing LockeT suture retention device to internal closure devices for post-catheter procedures. First 3 patients enrolled of planned 100.

7 months ago

#VTAK Catheter Precision Announces the Start of Enrollment for the LockeT Compare Study

www.stocktitan.net/news/VTAK/catheter-preci...

0 0 0 0